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j ourna l homepage: www.e lsev ie r .com/ locate /ygynoGynecologic Oncology: Update 2012These are challenging, changing and uncertain times in health
care, academics, and industry. Innovation and collaboration are es-
sential for us to succeed in improving the lives of women with cancer.
In this rapidly evolving environment, Gynecologic Oncology provides a
conduit to communicate scientiﬁc and clinical advances that create
the foundation for evidence-based best practices. Creative initiatives
that enhance efﬁciency and improve clinical outcomes will provide
value-added affordable care for our patients. Laboratory-based dis-
coveries, clinical-translational insights, clinical trial outcomes, and
surgical advances are progressing at an accelerating pace, and Gyne-
cologic Oncology is committed to delivering high quality peer-
reviewed information to you in a timely manner. We've been able
to achieve this mission. Thanks to the support of our outstanding dep-
uty editors, editorial board members, reviewers, and authors—as well
as our publisher, Elsevier, and our Society, the Society of Gynecologic
Oncology.
In the three years since our new editorial team was handed the
baton, we have worked to introduce innovations and enhancements
that would improve the Journal's service to our community. Online
access to articles and table of contents alerts have been expanded. Re-
view and publication times for new manuscripts have fallen, while
the number of submissions has continued to rise. In the last year,
more than 1150manuscripts were submitted by authors representing
50 countries—demonstrating the global reach of the Journal. The av-
erage time between submission to ﬁrst decision fell to just 15 days,
and the time from acceptance to online publication is now only
22 days. Themed special issues were published to focus on topics of
burgeoning interest such as New Biomarkers and Risk Predictors for
Prevention and Early Detection, Technological Innovations and
Novel Surgical Approaches, and most recently, our special issue focus-
ing on Survivorship and CAM. We introduced a biannual State of the
Science series to provide treatment updates on individual gynecologic
cancers, and our meeting reports have informed our readers of the
“hot topics” presented and discussed at national and international
scientiﬁc meetings of interest.
The Journal has focused on publishing original research as well as
other relevant editorials, commentaries, and reviews while maintain-
ing transparency and promoting the highest integrity in scientiﬁc
publication. Intensely aware of the heightened scrutiny of publication
ethics, we carefully review conﬂicts of interest for authors, reviewers0090-8258 © 2011 Published by Elsevier Inc.
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Open access under CC BY-NC-ND license.and editors. Submissions are screened for redundancy and plagiarism,
appropriateness of authorship and ghost writing, and IRB approval
and ethical conduct of research. Manuscripts are reviewed by our sta-
tistical consultant to help assure the validity of study design and con-
clusions prior to publication.
Earlier this year we launched Gynecologic Oncology Case Reports.
This new open access journal provides a timely and more accessible
portal for publishing challenging and instructive clinical scenarios and
experiences. Another exciting innovation is the publication of peer-
reviewed surgical ﬁlms that will be referenced in PubMed. With all of
this activity, we recruited two new deputy editors. Dr. Laurel Rice
from the University of Wisconsin and Dr. David Cohn from the Ohio
State University will help us continue to grow, improve and innovate.
The Journal has remained focused on scientiﬁc quality and serving
the interests of our diverse constituency. Metrics have included the
total number of manuscript citations (representing usage of the infor-
mation we publish), as well as the Journal's impact factor. The 2010
impact factor was 3.760 representing an increase of 44% since 2007.
This remarkable rise in Gynecologic Oncology's impact factor can be at-
tributed to the high quality of the research submitted by our authors,
as well as the Journal's ongoing innovative initiatives. We have also
worked to elevate the Journal's proﬁle through collaboration and
co-marketing with our health science colleagues including Lancet On-
cology, Cancer Cell, Fertility and Sterility, and the American Journal of
Obstetrics and Gynecology. These efforts have taken the form of print
ads, electronic banners, e-blasts, and listing on obgynadvance.com.
In the coming year, we can be certain that we'll encounter more
changes and new challenges. You have my commitment that Gyneco-
logic Oncologywill continue to do view these situations as opportuni-
ties, and embrace the imperative for ongoing innovation and
collaboration. We welcome your ideas and input regarding the Jour-
nal's performance and how we can better serve you. Ever the opti-
mist, I believe we can continue to expand the Journal's inﬂuence
and service to our community as long as we remain focused on our
core values of high quality and unimpeachable integrity. In so doing,
we will get closer to our ultimate goal of improving care for women
with cancer.
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